Clinical research of safety and efficacy after a stop of dasatinib administration in patients with chronic myeloid leukemia -chronic phase (CML-CP) achieving a complete molecular response (CMR) on a treatment of tyrosine kinase inhibitors (TKIs). - Stop dasatinib study (STDAST)

CML stem cell study group0 个研究点目标入组 141 人开始时间: 2012年8月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients who attend other clinical trial. 2) BCR-ABL point mutation (T315I, F317L, V299L) 3) QTc interval prolongation (>450msec) 4) Patient who has clear pleural effusion 5) Patients who have the following cardiovascular dysfunction 1. Impossible to measure QT interval in ECG 2. Complete left bundle branch block 3. Internal pacemaker 4. Congenital long QT syndrome or family history 5. Tachycardia 6. Bradycardia (<50bpm) 7. Myocardial infarction within 6 months 8. Angina pectoris within 3 months 9. Congestive heart failure within 3 months 10. Patient who have the complications of cardiovascular disorder 6) Active double cancer 7) Pregnant or breastfeeding woman 8) Patient who have complications with serious or poor control 9) Mental disorder 10) Cognitive dysfunction 11) Patient who judges the investigator to have difficulty in participation in study.

发起方

CML stem cell study group